Premium
Evaluation of eugenol for mutagenicity by the mouse micronucleus test
Author(s) -
Woolverton C. J.,
Fotos P. G.,
Mokas M. J.,
Mermigas M. E.
Publication year - 1986
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.1986.tb00656.x
Subject(s) - eugenol , micronucleus test , saline , chemistry , micronucleus , in vivo , pharmacology , population , toxicity , toxicology , medicine , biology , anesthesia , microbiology and biotechnology , environmental health , organic chemistry
Mutagenicity of eugenol (2‐methoxy‐4‐allylphenol) was evaluated by an in vivo eukaryotic assay in mice. A 50% lethal dose (LD 50 ) for intraperitoneal (IP) delivery of eugenol was found to be 1109.6 mg/kg body weight (7.5% eugenol‐in‐saline). Oral (PO) delivery via stainless‐steel, esophageal cannulation was not lethal to 14,794 mg/kg body weight (100%) eugenol. Based upon recommended procedure, HO and 25% LDW doses were administered IP in 250 μl volumes. Undiluted eugenol was administered PO in 100 μl volumes. Delivery of eugenol by both regimes to male mice induced anaphase mutations in polychromatic erythrocytes as measured by the bone marrow micronucleus test. IP delivery of both doses induced the formation of micronuclei to significant levels (P <0.001) compared to saline controls. PO delivery of eugenol induced a much reduced frequency of micronuclei when compared to the IP route. However, a significant increase in micronuclei was evident when this test population was compared to its control group (P <0.003). These results suggest that eugenol presents some mutagenic capacity in eukaryotic hosts and should be evaluated for further toxicological effects.